about
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's diseaseClioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse modelCloning, expression, purification, crystallization and preliminary crystallographic analysis of pseudo death-effector domain of HIPPI, a molecular partner of Huntingtin-interacting protein HIP-1Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington diseaseDiminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neuronsHuntington's disease: roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcriptionGenome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's diseaseN-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by Zika Virus InfectionTranscriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.Development of a method for the high-throughput quantification of cellular proteins.Inositol trisphosphate receptor Ca2+ release channels in neurological diseases.Neurodegeneration: what is it and where are we?The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases.Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders.Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease.Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.The corticostriatal pathway in Huntington's disease.Mechanisms of neurodegeneration in Huntington's disease.Calpain-mediated signaling mechanisms in neuronal injury and neurodegenerationVaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC.Noninvasive quantification of metabotropic glutamate receptor type 1 with [¹¹C]ITDM: a small-animal PET study.Huntington's disease and Group I metabotropic glutamate receptors.Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteinsAnimal models of neurodegenerative diseases.Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, and In Vitro Disease Modeling.Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.IP3 receptor mutations and brain diseases in human and rodents.Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells.Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.mGluR5: a potential target for the treatment of Huntington's disease
P2860
Q24317702-BBAE9842-F120-4A04-874C-CE7469DE4524Q24535603-B5107E42-56F7-48BA-A0A9-9D2FBA191E3DQ24548047-603159DF-6F2F-4828-B60A-851D25F0E381Q24647950-1BFB4426-BF1B-4569-A1E8-298DE397AE20Q24656169-FF293CD6-9DF2-441A-B8B4-62045D9151C9Q24657764-6622A67D-D0AB-488A-8A9C-CC7A53CEC987Q28255372-DDE426F6-09DE-4479-8026-87B1473D836EQ28287646-3E99356D-B2A7-473C-909B-19CBD1A134AAQ28594357-6A09DCCC-B886-4058-BD35-13BC084C4C29Q30145688-5E67C8AA-5B84-4C75-89F3-1DB3B7434EAEQ31129663-91BA5F99-86E6-4412-BD89-9CBD3345048BQ33459352-901EB7A1-6362-4EFF-99ED-85D0338434A9Q33946097-5E551616-37AF-4F4E-87CC-544343AB1166Q34828270-5D2A580B-CA01-40E9-B3A5-AB5E63D0AB83Q35558500-CE3D8DA5-3143-469C-8BA1-F624D917E263Q35754469-DEA4011E-5606-4D8E-AD05-E37CF31CDB3FQ35754533-43F66413-77B1-4D19-AA23-0353FAD192E2Q35767283-E19F871C-B9A3-4949-97A6-95B284FF0055Q36122602-4EA4C9C3-9F0F-4118-8971-1AF97A4A5B59Q36501584-546534F2-6B32-4DB3-925C-C6CF751CD199Q36684263-7F1502AB-3ED4-46CF-9427-3538709290E7Q37202865-6BD88B1A-DCD5-4327-9AC5-2A8F5B34B640Q37237452-D7315B37-2BB5-40E3-81C5-43622F994409Q37546880-9ABA93D0-2C97-4DB4-94A1-E7D3373DC905Q37695328-AA322496-BF0B-48B0-A06A-7CEBD07816D3Q37820343-7B3F2EE2-31CA-499B-BFB6-D9EF2EB51604Q37961564-F041237A-B456-40E1-80A3-783D93498EDBQ38165759-5974051D-74D8-417B-B1DC-C4BD878716C4Q38531969-F3C63099-059D-4CA3-A81E-2977471061B4Q38957994-06C1D802-E690-4237-8CDE-1DFA31DE65B4Q39140608-00EB6838-4857-489A-9281-C9D416F845DCQ39567922-3A92BF8F-0525-4B91-84D8-0B6124E52E18Q43120924-34E766D0-7642-4996-B57F-E88150816A46Q45288978-3079C756-F092-4630-9BEF-DECFC3663765Q45296120-3079A800-7A30-462E-AD1E-2F8565166D48Q56796063-B807ABFA-A230-4173-84D6-DC858C6B25E7
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Huntingtin in health and disease
@ast
Huntingtin in health and disease
@en
Huntingtin in health and disease
@nl
type
label
Huntingtin in health and disease
@ast
Huntingtin in health and disease
@en
Huntingtin in health and disease
@nl
prefLabel
Huntingtin in health and disease
@ast
Huntingtin in health and disease
@en
Huntingtin in health and disease
@nl
P2860
P356
P1476
Huntingtin in health and disease
@en
P2093
Anne B Young
P2860
P304
P356
10.1172/JCI17742
P407
P577
2003-02-01T00:00:00Z